share_log

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer O'Hara Elaine

Novavax | 4: Statement of changes in beneficial ownership of securities

诺瓦瓦克斯医药 | 4：持股变动声明
美股sec公告 ·  03/26 19:05
Moomoo AI 已提取核心信息
Elaine O'Hara, EVP, Chief Strategy Officer at Novavax, Inc. [NVAX], was reported to have engaged in a transaction involving the company's stock on March 1, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action type and status of the transaction were also not provided. This information is critical for investors to understand the potential impact on their investment in Novavax.
Elaine O'Hara, EVP, Chief Strategy Officer at Novavax, Inc. [NVAX], was reported to have engaged in a transaction involving the company's stock on March 1, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action type and status of the transaction were also not provided. This information is critical for investors to understand the potential impact on their investment in Novavax.
据报道，Novavax, Inc. [NVAX] 执行副总裁兼首席战略官伊莱恩·奥哈拉于2024年3月1日参与了一项涉及该公司股票的交易。公告中未披露该交易的具体细节，包括股票数量、股票性质、交易价格和股票总价值。也没有提供交易的操作类型和状态。这些信息对于投资者了解对Novavax投资的潜在影响至关重要。
据报道，Novavax, Inc. [NVAX] 执行副总裁兼首席战略官伊莱恩·奥哈拉于2024年3月1日参与了一项涉及该公司股票的交易。公告中未披露该交易的具体细节，包括股票数量、股票性质、交易价格和股票总价值。也没有提供交易的操作类型和状态。这些信息对于投资者了解对Novavax投资的潜在影响至关重要。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息